Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 4:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 6,437 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Renal Clear all
Completed Not applicable Interventional

Advanced Glycation End-products, Inflammation and Vascular Health in Chronic Kidney Disease

NCT01769963
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Research diet
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 1, 2014 · Synced Oct 27, 2026, 4:34 AM EDT
Completed No phase listed Observational

Vasopressin Plasma Concentrations in Patients Receiving Exogenous Vasopressin Infusion for Septic Shock

NCT03014063
View directory record Official record
Conditions
Septic Shock
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 31, 2019 · Synced Oct 27, 2026, 4:34 AM EDT
Completed Phase 2 Interventional Results available

Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma

NCT00496587
View directory record Official record
Conditions
Renal Cell Carcinoma, Kidney Cancer
Interventions
Capecitabine, Gemcitabine, Bevacizumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 19, 2017 · Synced Oct 27, 2026, 4:34 AM EDT
Recruiting Not applicable Interventional

Nephroureterectomy With and Without Lymph Node Dissection for Upper Tract Urothelial Cell Carcinoma

NCT06262516
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
Nephroureterectomy, Lymph Node Dissection
Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
19 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
4
States / cities
Gainesville, Florida • Springfield, Illinois • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 27, 2026, 4:34 AM EDT
Completed Phase 2 Interventional

A Comparison of the Effects of Aleglitazar and Actos on Renal Function on Patients With Type 2 Diabetes.

NCT00461006
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
Actos, aleglitazar
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
16
States / cities
Peoria, Arizona • Jonesboro, Arkansas • Fresno, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2016 · Synced Oct 27, 2026, 4:34 AM EDT
Completed Phase 2 Interventional Results available

Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)

NCT03233204
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma, Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma, Low Grade Glioma, Malignant Glioma, Recurrent Childhood Central Nervous System Neoplasm, Recurrent Childhood Ependymoma, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Non-Hodgkin Lymphoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Refractory Childhood Malignant Germ Cell Tumor, Refractory Ependymoma, Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Refractory Glioma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Primary Central Nervous System Neoplasm, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Rhabdoid Tumor, Wilms Tumor
Interventions
Olaparib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
111
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 88 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Oct 27, 2026, 4:34 AM EDT
Completed Phase 4 Interventional Results available

Vasopressin Administration During Laparoscopic Myomectomy: a Randomized Controlled Trial

NCT01393704
View directory record Official record
Conditions
Blood Loss, Surgical
Interventions
Vasopressin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 15, 2018 · Synced Oct 27, 2026, 4:34 AM EDT
Completed Phase 4 Interventional Results available

Treatment of Resistant Nephrotic Syndrome With ACTH Gel (ACTHAR)

NCT01129284
View directory record Official record
Conditions
Treatment Resistant Nephrotic Syndrome
Interventions
ACTHAR gel
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2014 · Synced Oct 27, 2026, 4:34 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Cinacalcet in Pediatric Patients With Secondary Hyperparathyroidism (SHPT) and Chronic Kidney Disease (CKD) on Dialysis

NCT02138838
View directory record Official record
Conditions
Chronic Kidney Disease, Secondary Hyperparathyroidism
Interventions
Cinacalcet HCl, Standard of Care
Drug · Dietary Supplement
Lead sponsor
Amgen
Industry
Eligibility
6 Years to 17 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
26
States / cities
Los Angeles, California • Wilmington, Delaware • Atlanta, Georgia + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2020 · Synced Oct 27, 2026, 4:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessing the Pharmacokinetics of NKTR-118 in Subjects With Renal Impairment Compared to That in Subjects With Normal Renal Function

NCT01372826
View directory record Official record
Conditions
Renal Impairment
Interventions
NKTR118 Group1, NKTR118 Group 2, NKTR118 Group3, NKTR118
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
3
States / cities
Anaheim, California • Orlando, Florida • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2014 · Synced Oct 27, 2026, 4:34 AM EDT
Recruiting Phase 2 Interventional

Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...

NCT06161532
View directory record Official record
Conditions
Small Cell Carcinoma of the Bladder, Small Cell Carcinoma of the Urinary Tract, Squamous Cell Carcinoma of the Bladder, Squamous Cell Carcinoma of the Urinary Tract, Primary Adenocarcinoma of the Bladder, Primary Adenocarcinoma of the Urinary Tract, Renal Medullary Carcinoma, Squamous Cell Carcinoma of the Penis
Interventions
Sacituzumab govitecan, Atezolizumab
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 27, 2026, 4:34 AM EDT
Recruiting Not applicable Interventional

taVNS for FRNS in Children

NCT05588063
View directory record Official record
Conditions
Nephrotic Syndrome in Children, Minimal Change Disease, Focal Segmental Glomerulosclerosis
Interventions
Transcutaneous auricular vagus nerve stimulation, Sham device
Device
Lead sponsor
Northwell Health
Other
Eligibility
3 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
New Hyde Park, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 27, 2026, 4:34 AM EDT
Recruiting Not applicable Interventional

A Study of Facilitators and Barriers to Improve Acute Kidney Injury in Children Through Mobile Health Intervention

NCT04403633
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
mobile health educational tool
Other
Lead sponsor
Duke University
Other
Eligibility
1 Year to 18 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 27, 2026, 4:34 AM EDT
Terminated Phase 1 Interventional

Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies

NCT06052852
View directory record Official record
Conditions
Triple Negative Breast Cancer, Clear Cell Renal Cell Carcinoma, Ovarian Cancer, Head and Neck Cancer, Colorectal Cancer, Non-small Cell Lung Cancer, Melanoma
Interventions
BDC-3042, Cemiplimab
Drug
Lead sponsor
Bolt Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
Palo Alto, California • Boston, Massachusetts • Austin, Texas + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Oct 27, 2026, 4:34 AM EDT
Active, not recruiting Phase 4 Interventional

Nitrite-boosting Therapy for Improving Physiological Function in Patients With Chronic Kidney Disease

NCT03826147
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Nitrate-rich beetroot juice, Nitrate-depleted beetroot juice
Dietary Supplement
Lead sponsor
University of Colorado, Boulder
Other
Eligibility
30 Years to 80 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 27, 2026, 4:34 AM EDT
Completed No phase listed Observational

Cardiopulmonary Inflammation and Multi-System Imaging During the Clinical Course of COVID-19 Infection in Asymptomatic and Symptomatic Persons

NCT04401449
View directory record Official record
Conditions
Acute and Long Term Effects of COVID-19 on Systemic Inflammation, Acute and Long Term Effects of COVID-19 on Lung Function, Acute and Long Term Effects of COVID-19 on Cardiac Function, Acute and Long Term Effects of COVID-19 on Kidney Function, Acute and Long Term Effects of COVID-19 on Brain Function
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 80 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 27, 2026, 4:34 AM EDT
Completed Phase 1Phase 2 Interventional

Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Stage IV Kidney Cancer

NCT00005851
View directory record Official record
Conditions
Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
Interventions
fludarabine phosphate, total-body irradiation, nonmyeloablative allogeneic hematopoietic stem cell transplantation, cyclosporine, mycophenolate mofetil, peripheral blood stem cell transplantation, therapeutic allogeneic lymphocytes, laboratory biomarker analysis
Drug · Radiation · Procedure + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 74 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2018
U.S. locations
6
States / cities
Tucson, Arizona • Aurora, Colorado • Dallas, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Oct 27, 2026, 4:34 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Bone in CKD Alkali Response (BICARb Pilot Trial)

NCT05918029
View directory record Official record
Conditions
Chronic Kidney Diseases, Bone Loss
Interventions
Potassium Citrate Extended Release Oral Tablet, Placebo, Potassium Citrate and Citric Acid Oral Solution
Drug · Other
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
5 Years to 100 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
The Bronx, New York • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 27, 2026, 4:34 AM EDT
Terminated Phase 4 Interventional Results available

A Study of Ferric Citrate to Improve Inflammation and Lipid Levels

NCT02661295
View directory record Official record
Conditions
End Stage Renal Disease, Hyperphosphatemia, Chronic Inflammation
Interventions
Ferric Citrate
Drug
Lead sponsor
Winthrop University Hospital
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced Oct 27, 2026, 4:34 AM EDT
Terminated Phase 2 Interventional Results available

Isosorbide Mononitrate For Anti-Vascular Endothelial Growth Factor (VEGF) Induced Kidney Injury

NCT04051957
View directory record Official record
Conditions
Kidney Injury, Proteinuria, Hypertension
Interventions
Isosorbide Mononitrate, Placebo oral tablet
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 3, 2022 · Synced Oct 27, 2026, 4:34 AM EDT
Recruiting Phase 2 Interventional

A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases

NCT05048212
View directory record Official record
Conditions
Brain Metastases, Renal Cell Carcinoma
Interventions
Nivolumab, Ipilimumab, Cabozantinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 27, 2026, 4:34 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Representational Intervention to Promote Preparation for End-of-life Decision Making

NCT01259011
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
the SPIRIT intervention
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Oct 27, 2026, 4:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Of SB-497115 in Healthy Subjects and Subjects With Mild, Moderate or Severe Renal Impairment

NCT00442871
View directory record Official record
Conditions
Purpura, Thrombocytopaenic, Idiopathic
Interventions
eltrombopag
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
2
States / cities
Gainesville, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 27, 2026, 4:34 AM EDT
Recruiting No phase listed Observational

FST Analysis Supporting Timely Therapy and Risk Assessment Via Clinical Decision Support for Kids

NCT07718464
View directory record Official record
Conditions
Acute Kidney Injury, Renal Replacement Therapy, Pediatric Intensive Care Unit
Interventions
Furosemide Stress Test Clinical Decision Support Tool
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 27, 2026, 4:34 AM EDT